Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure.

@article{Martn2004PhaseIS,
  title={Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure.},
  author={Miguel Angel Mart{\'i}n and Jes{\'u}s Garc{\'i}a-Donas and Antonio Cuevas Casado and Isabel de la G{\'a}ndara and Pedro P{\'e}rez-Segura and Jos{\'e}-{\'A}ngel Garc{\'i}a-S{\'a}enz and Gabriel Ib{\'a}{\~n}ez and Belen Loboff and Gemma Garc{\'i}a-Ledo and Fernando Moreno and Enrique Grande and Eduardo Diaz-Rubio},
  journal={Clinical breast cancer},
  year={2004},
  volume={5 5},
  pages={353-7}
}
Thirty-five patients with metastatic breast cancer (MBC) entered a phase II study of pegylated liposomal doxorubicin 35 mg/m2 intravenously (i.v.) on day 1 plus vinorelbine 30 mg/m2 i.v. on day 1 every 4 weeks. Patients were required to have measurable disease, previous chemotherapy with an anthracycline-containing regimen, and a normal left ventricular ejection fraction (LVEF). Thirty-four patients were assessable for response and toxicity. The overall response rate (on an intent-to-treat… CONTINUE READING
9 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…